WCLC 2022 Conference Coverage


 

WCLC 2022 on the Phase 3 SANOVO Study: Savolitinib or Placebo in Combination With Osimertinib in EGFRm and MET Overexpressed NSCLC

169 views
August 18, 2022
Comments 0
Login to view comments. Click here to Login